TRIM33 and dermatomyositis: IMACS 2023 provides a risk-stratified screening framework: basic screening for all adults at diagnosis; add an “enhanced” panel (e.g., CT, tumor markers) for moderate/high risk; and consider 18F-FDG PET-CT as a single screen in anti-TIF1-γ-positive DM onset >40 years with other high-risk features.